Skip to content

Clinical study of the treatment of Nvzhen Decoction on decreased ovarian function with TCM syndrome of kidney deficiency and liver depression

Clinical study of the treatment of Nvzhen Decoction on decreased ovarian function with TCM syndrome of kidney deficiency and liver depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000870
Enrollment
Unknown
Registered
2025-04-28
Start date
2022-04-18
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decreased ovarian function

Interventions

control group:Progynova and Dydrogesterone Tablets
TCM group:Nvzhen Decoction+Progynova and Dydrogesterone Tablets

Sponsors

Beijing Obstetrics and Gynecology Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 38 Years

Inclusion criteria

Inclusion criteria: 1) Meets the diagnostic criteria of Western medicine for 'decreased ovarian reserve function'; 2) Meets the diagnostic criteria of traditional Chinese medicine for kidney deficiency and liver depression syndrome; 3) Age: between 20-38 years old; 4) Informed consent and volunteer for the project and truthful answers to survey questions.

Exclusion criteria

Exclusion criteria: 1) Individuals with congenital gonadal hypoplasia and acquired organic diseases leading to menstrual disorders; 2) Patients with menstrual disorders caused by endocrine disorders such as polycystic ovary syndrome hyperprolactinemia dysfunctional uterine bleeding hypogonadotropin hypothyroidism etc; 3) Individuals with a history of attachment surgery; 4) Have a history of autoimmune diseases pelvic infectious diseases mumps etc; 5) Individuals with a history of using reproductive toxic drugs chemotherapy drugs or radiotherapy; 6) Suspected genetic factors of ovarian decline; 7) Those who have taken hormone therapy within six months; 8) Pregnant or lactating women; 9) Patients with severe mental illness who cannot ensure the authenticity and accuracy of the questionnaire filled out; 10) I have participated in other clinical trials within the past three months.

Design outcomes

Primary

MeasureTime frame
anti-Müllerian hormone;sex hormones;inhibin B;

Secondary

MeasureTime frame
GAD-7;Adrenocorticotropic Hormone(ACTH);PHQ-9;TCM Symptom Score;Menstrual Score;cortisol;Antral Follicle Count;

Countries

China

Contacts

Public ContactGuan Siqi

Beijing Obstetrics and Gynecology Hospital Capital Medical University

guansiqi@ccmu.edu.cn15869132758

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026